DHR trades against a final fair-value range of $122.72-$203.68, with the midpoint set by the accepted valuation synthesis rather than earlier draft model outputs. Fair value range: low $123, high $204, with mid-point at $163.
Stock analysis
Danaher CorporationDHR Danaher Corporation fair value $163–$204
Trades close to fair value, so the margin of safety is limited either way.
Fair value
$163
Margin of safety
-4.9%
Confidence
87/100
Moat
9/10
Educational analysis only — not financial advice. Always do your own due diligence.
$171.16Price
FV $163.1
High $203.68
DHR trades against a final fair-value range of $122.72-$203.68, with the midpoint set by the accepted valuation synthesis rather than earlier draft model outputs.
Based on our latest independent analysis, DHR trades close to fair value. The current price is $171 versus a composite fair-value midpoint of $163 (range $123–$204), which implies roughly 4.7% downside to the midpoint.
Our composite fair-value range for DHR is $123–$204, with a midpoint of $163. The range is triangulated across multiple valuation models (discounted earnings, forward earnings scenarios, peer multiples, and where applicable owner earnings or reverse DCF) and weighted by reliability for Danaher Corporation's archetype.
Our current rating for DHR is Hold with a confidence score of 87/100. DHR is rated Hold at $171.16 versus the reconciled fair value midpoint of $163.10, implying -4.71% upside/downside. Confidence is separately disclosed at 87/100. This is independent research for educational purposes, not personalized investment advice.
The top risks our latest report flags for Danaher Corporation are: Prolonged Bioprocessing Slump; M&A Integration Failure; China Market Deterioration. The single biggest risk is Consensus is overly optimistic on perpetual growth.
Our current rating for DHR is Hold, issued with a confidence score of 87/100 and a moat score of 9/10. The rating reflects the composite fair-value range ($123–$204) versus the current price of $171.
Danaher Corporation is classified as a mature compounder stock. Archetype determines how every downstream parameter — discount rate, terminal growth, deceleration curve, terminal multiple, scenario probability weights, scorecard weights, and which valuation models are prioritized — is calibrated for DHR.
